정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1521 | Recruiting | Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial | Covid19 | Drug: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases | Phase 3 | Helwan University, Ain Shams University, Fayoum University, Assiut University, Tanta University, National Institute of Infectious Diseases, Tokyo, Japan | OTHER | 1500 | All | 18 Years ~ 65 Years | Helwan University, Cairo, Egypt |
| 1520 | Recruiting | Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers. | Coronavirus Infection | Drug: Melatonin 2mg Drug: Placebo oral tablet |
Phase 3 | Instituto de Investigacion Hospital Universitario La Paz | OTHER | 450 | All | 18 Years ~ 65 Years | Hospital Universitario La Paz, Madrid, Spain |
| 1519 | Not yet recruiting | Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19: | SARS (Disease) | Drug: Montelukast Other: placebo |
Phase 3 | Jordi Gol i Gurina Foundation, Institut Catala de la Salut | OTHER | 284 | All | 18 Years ~ 80 Years | |
| 1518 | Recruiting | Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19 | COVID-19 | Drug: 0.5% Povidone Iodine Drug: 0.12% Chlorhexidine Gluconate Mouth Rinse Drug: 1% Hydrogen Peroxide Drug: 0.9% Normal Saline |
Phase 4 | Ohio State University | OTHER | 60 | All | 18 Years ~ 80 Years | The Ohio State University Wexner Medical Center, Columbus, Ohio, United States |
| 1517 | Recruiting | Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva | Coronavirus | Drug: Corsodyl® Alcohol free -0.2 % Chlorhexidine digluconate Drug: Colgate Peroxyl® -1.5% Hydrogen peroxide Other: Oral-B® Gum & Enamel Care -Cetylpyridinium chloride Other: No rinsing |
Not Applicable | Queen Mary University of London, GlaxoSmithKline | OTHER | 40 | All | 18 Years | Newham Hospital, London, United Kingdom Royal London Hospital, London, United Kingdom |
| 1516 | Completed | Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease | Oxidative Stress | Drug: N-acetylcysteine | Phase 2 | Cambridge Health Alliance | OTHER | 165 | All | 18 Years | CHA Cambridge Hospital, Cambridge, Massachusetts, United States CHA Everett Hospital, Everett, Massachusetts, United States CHA Respiratory Clinic, Somerville, Massachusetts, United States CHA Somerville campus, Somerville, Massachusetts, United States |
| 1515 | Recruiting | Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) | COVID19 | Drug: Nafamostat Mesilate Drug: Placebo |
Phase 3 | University Hospital Padova, Yokohama City University, University of Zurich | OTHER | 256 | All | 18 Years ~ 85 Years | Azienda Ospedale Universita di Padova, Padova, Italy |